Limpid Markets
← Back to Intelligence

Aptamer Group reports 27% revenue growth on pharma contracts

Investing.com Gold Tier 2 2026-03-25 07:51 UTC 📖 1 min read Neutral

Investing.com Gold reports: Aptamer Group reports 27% revenue growth on pharma contracts. Full body text was unavailable at ingest time, so this brief is based on headline context.

↗ Read Original